These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

400 related articles for article (PubMed ID: 31728838)

  • 41. SOURCE: a phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel group trial to evaluate the efficacy and safety of tezepelumab in reducing oral corticosteroid use in adults with oral corticosteroid dependent asthma.
    Wechsler ME; Colice G; Griffiths JM; Almqvist G; Skärby T; Piechowiak T; Kaur P; Bowen K; Hellqvist Å; Mo M; Garcia Gil E
    Respir Res; 2020 Oct; 21(1):264. PubMed ID: 33050928
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Benralizumab for the add-on maintenance treatment of patients with severe asthma aged 12 years and older with an eosinophilic phenotype.
    Al Efraij K; FitzGerald JM
    Expert Rev Clin Pharmacol; 2018 Jul; 11(7):669-676. PubMed ID: 29972739
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Dupilumab efficacy and safety in Japanese patients with uncontrolled, moderate-to-severe asthma in the phase 3 LIBERTY ASTHMA QUEST study.
    Tohda Y; Nakamura Y; Fujisawa T; Ebisawa M; Arima K; Miyata M; Takahashi Y; Rice MS; Deniz Y; Rowe P; Patel N; Graham NMH; Teper A
    Allergol Int; 2020 Oct; 69(4):578-587. PubMed ID: 32444306
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A review of dupilumab in the treatment of atopic diseases.
    Thibodeaux Q; Smith MP; Ly K; Beck K; Liao W; Bhutani T
    Hum Vaccin Immunother; 2019; 15(9):2129-2139. PubMed ID: 30785362
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Real-world impact of dupilumab on asthma disease burden in Japan: The CROSSROAD study.
    Fukunaga K; Tagaya E; Ishida M; Sunaga Y; Koshiba R; Yokoyama A
    Allergol Int; 2023 Oct; 72(4):537-544. PubMed ID: 37117134
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Dupilumab Is Effective in Patients With Moderate-to-Severe Uncontrolled GINA-Defined Type 2 Asthma Irrespective of an Allergic Asthma Phenotype.
    Rabe KF; FitzGerald JM; Bateman ED; Castro M; Pavord ID; Maspero JF; Busse WW; Izuhara K; Daizadeh N; Ortiz B; Pandit-Abid N; Rowe PJ; Deniz Y
    J Allergy Clin Immunol Pract; 2022 Nov; 10(11):2916-2924.e4. PubMed ID: 36028446
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Impact of dupilumab across seasons in patients with type 2, uncontrolled, moderate-to-severe asthma.
    Peters AT; Sagara H; Corren J; Domingo C; Altincatal A; Soler X; Pandit-Abid N; Crikelair N; Rowe PJ; Jacob-Nara JA; Deniz Y
    Ann Allergy Asthma Immunol; 2024 Apr; 132(4):477-484.e4. PubMed ID: 38013139
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Long-Term Effectiveness of Anti-IL-4R Therapy Following Suboptimal Response to Anti-IL-5/5R Therapy in Severe Eosinophilic Asthma.
    Gates J; Hearn A; Mason T; Fernandes M; Green L; Thomson L; Roxas C; Lam J; d'Ancona G; Nanzer AM; Dhariwal J; Jackson DJ
    J Allergy Clin Immunol Pract; 2024 Jul; 12(7):1794-1800. PubMed ID: 38583517
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Anti-IL-4/IL-13 for the treatment of asthma: the story so far.
    Moran A; Pavord ID
    Expert Opin Biol Ther; 2020 Mar; 20(3):283-294. PubMed ID: 31914819
    [No Abstract]   [Full Text] [Related]  

  • 50. Dupilumab therapy for patients with refractory eosinophilic otitis media associated with bronchial asthma.
    Iino Y; Sekine Y; Yoshida S; Kikuchi S
    Auris Nasus Larynx; 2021 Jun; 48(3):353-360. PubMed ID: 32943257
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Low Serum IL-18 Levels May Predict the Effectiveness of Dupilumab in Severe Asthma.
    Watanabe S; Suzukawa M; Tashimo H; Ohshima N; Asari I; Takada K; Imoto S; Nagase T; Ohta K
    Intern Med; 2024 Jan; 63(2):179-187. PubMed ID: 37225484
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma.
    Lanier B; Bridges T; Kulus M; Taylor AF; Berhane I; Vidaurre CF
    J Allergy Clin Immunol; 2009 Dec; 124(6):1210-6. PubMed ID: 19910033
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Real-life rapidity of benralizumab effects in patients with severe allergic eosinophilic asthma: Assessment of blood eosinophils, symptom control, lung function and oral corticosteroid intake after the first drug dose.
    Pelaia C; Busceti MT; Vatrella A; Rago GF; Crimi C; Terracciano R; Pelaia G
    Pulm Pharmacol Ther; 2019 Oct; 58():101830. PubMed ID: 31344472
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Dupilumab Improves Asthma Control and Lung Function in Patients with Insufficient Outcome During Previous Antibody Therapy.
    Mümmler C; Munker D; Barnikel M; Veit T; Kayser MZ; Welte T; Behr J; Kneidinger N; Suhling H; Milger K
    J Allergy Clin Immunol Pract; 2021 Mar; 9(3):1177-1185.e4. PubMed ID: 32980583
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Mepolizumab: First Global Approval.
    Keating GM
    Drugs; 2015 Dec; 75(18):2163-9. PubMed ID: 26603873
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The long-term effect of dupilumab on dyspnea, sleep, and activity in oral corticosteroid-dependent severe asthma.
    Sher LD; Passalacqua G; Taillé C; Cohn L; Daizadeh N; Pandit-Abid N; Soler X; Khodzhayev A; Jacob-Nara JA; Deniz Y; Rowe PJ; Nag A; Zhang Y
    Ann Allergy Asthma Immunol; 2023 Mar; 130(3):298-304. PubMed ID: 36509407
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Baseline FeNO Independently Predicts the Dupilumab Response in Patients With Moderate-to-Severe Asthma.
    Pavord ID; Deniz Y; Corren J; Casale TB; FitzGerald JM; Izuhara K; Daizadeh N; Ortiz B; Johnson RR; Harel S; Djandji M; Goga L; Crikelair N; Rowe PJ; Busse WW
    J Allergy Clin Immunol Pract; 2023 Apr; 11(4):1213-1220.e2. PubMed ID: 36535524
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effect of exacerbation history on clinical response to dupilumab in moderate-to-severe uncontrolled asthma.
    Corren J; Katelaris CH; Castro M; Maspero JF; Ford LB; Halpin DMG; Rice MS; Radwan A; Deniz Y; Rowe PJ; Teper A; Djandji M
    Eur Respir J; 2021 Oct; 58(4):. PubMed ID: 34266940
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Targeting the interleukin-4 and interleukin-13 pathways in severe asthma: current knowledge and future needs.
    Parulekar AD; Kao CC; Diamant Z; Hanania NA
    Curr Opin Pulm Med; 2018 Jan; 24(1):50-55. PubMed ID: 29036019
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Efficacy and safety of treatment with dupilumab for severe asthma: A systematic review of the EAACI guidelines-Recommendations on the use of biologicals in severe asthma.
    Agache I; Song Y; Rocha C; Beltran J; Posso M; Steiner C; Alonso-Coello P; Akdis C; Akdis M; Canonica GW; Casale T; Chivato T; Corren J; Del Giacco S; Eiwegger T; Firinu D; Gern JE; Hamelmann E; Hanania N; Mäkelä M; Martín IH; Nair P; O'Mahony L; Papadopoulos NG; Papi A; Park HS; Pérez de Llano L; Quirce S; Sastre J; Shamji M; Schwarze J; Canelo-Aybar C; Palomares O; Jutel M
    Allergy; 2020 May; 75(5):1058-1068. PubMed ID: 32154939
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.